An interventional study of Transcranial Magnetic Stimulation (TMS) in Misophonia, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.
Icahn School of Medicine at Mount Sinai is the lead sponsor of 764 studies on the registry; 181 are open to participants now.
Of its 121 completed or terminated interventional studies of FDA-regulated products, 82 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants in this group will receive an inhibitory TMS in the first session and an excitatory TMS in the second session. The two sessions will be separated by 72 hours.
Other: Transcranial Magnetic Stimulation (TMS)
Participants in this group will receive an excitatory TMS in the first session and an inhibitory TMS in the second session. The two sessions will be separated by 72 hours.
Other: Transcranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
Unpleasantness Rating Scale
Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness
Time frame: after each session, 72 hours apart (each session is 2 hours)
Heart Rate
The heart rate (number of beats per minute) will be measured using a wristwatch worn by the participant.
Time frame: after each session, 72 hours apart (each session is 2 hours)
Skin Conductance Response
Skin conductance, a measure capturing the amount of sweat, will be measured using a wristwatch worn by the participant.
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG P1-N1-P2 Complex Peak Amplitude
Amplitude (microvolts) of P1, N1, and P2 peaks measured in the parietal region
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG P1-N1-P2 Complex Peak Latency
Latency (milliseconds) of P1, N1, and P2 peaks measured in the parietal region
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG Frequency Band Amplitude
Amplitude (decibel) in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG Frequency Band Inter-Trial Coherence
Coherence (unitless) across trials in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region
Time frame: after each session, 72 hours apart (each session is 2 hours)
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Sap
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
misophonia
Icahn School of Medicine at Mount Sinai